CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
We are very excited to launch our new website! Please take a few moments to click around and explore...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...